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Background: Several guidelines, including the Japanese Pediatric Guideline for the Treatment and
Management of Asthma (JPGL), recommend salmeterol/ﬂuticasone combination therapy (SFC) as step 3
to 4 treatment for moderate to severe asthma. However, the optimal step-down approach to SFC remains
unclear. In the current study, we examined step-down approaches in asthmatic children whose symp-
toms had been stabilized by SFC 100/200 mg/day.
Methods: This randomized, multicenter, open-label, parallel-group study was conducted over 12 weeks.
For step-down therapy, subjects aged 5e15 years were randomly assigned to an SFC group (25/50 mg
b.i.d.) or an FP group (100 mg b.i.d.), and treated for 12 weeks. Childhood Asthma Control Test (C-ACT)
scores, lung function, and exhaled nitric oxide (FeNO) levels were monitored.
Results: Of 131 enrolled subjects, 128 completed the study and were included in the analysis. Decreases
in % peak expiratory ﬂow rate and % forced expiratory ﬂow at 50% of vital capacity (V50) were observed
in the FP group at each time point. There was a signiﬁcant difference between the two groups for the
change in %V50 from its previous value at each time point. There were no signiﬁcant changes in FeNO
levels (range 15e20 ppb) or C-ACT scores (~26 points) within or between groups.
Conclusions: A high level of asthma control was maintained with both approaches. The use of SFC
step-down resulted in somewhat better respiratory function, with no worsening of airwayJikei University Daisan Hospital, 4-11-1, Izumi-honchou, Komae, Tokyo 201-8601, Japan.
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FeNO exhaled nitric oxideinﬂammation. However, halving the dose of SFC and switching to FP alone are both optimal step-down
approaches.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The 2008 and 2012 editions of the Japanese Pediatric Guideline
for the Treatment and Management of Asthma (JPGL) recommend
salmeterol/ﬂuticasone combination therapy (SFC) as step 3 to 4
treatment to control moderate or more severe asthma in children
aged 5e15 years.1 The JPGL recommends an SFC dose based on
ﬂuticasone 100e200 mg/day (salmeterol/ﬂuticasone 50/100e100/
200 mg/day; hereafter, the SFC dose is reported as the ﬂuticasone
dose only) for step 3 therapy and 200 mg/day for step 4 therapy. A
2012 report from the Global Initiative for Asthma similarly rec-
ommends SFC as a step 3 or 4 therapy.2
Once effective asthma control is achieved with inhaled corti-
costeroids (ICS), treatment needs to be stepped down to maintain
asthma control with the minimum necessary dose. However, the
optimal step-down approach following control achieved with SFC
remains unclear. In adult asthma patients controlled with SFC
500 mg/day, treatment can be effectively stepped down by changing
to SFC 200 mg/day rather than changing to an equivalent dose of ICS
[i.e., stopping the long-acting b2 agonist (LABA)].3 Furthermore,
previous research has indicated that the anti-asthma effect of ﬂu-
ticasone propionate (FP) 100 mg/day in combination with salme-
terol (SFC) is equivalent to treatment with FP 200 mg/day alone.4
Once childhood asthma is stable for 3 months, the JPGL suggests
stepping down treatment by stopping the b2 agonist. Therefore, the
JPGL recommends a change from SFC to FP alone. This approach
might be based in part on the ﬁndings of the SMART trial,5 which
suggested that long-term use of salmeterol without an ICS could
potentially cause increased airway inﬂammation and consequent
worsening of asthma symptoms. In fact, another study found that
while asthma control with FP 200 mg/day was superior to SFC
100 mg/day in children, the reverse held true in adults.6 However,
there is limited clinical evidence to support the superiority of ICS
alone over SFC in pediatric asthma patients.
In the current study, we investigated the optimal step-down
approach in asthmatic children whose symptoms had been stabi-
lized with SFC 200 mg/day. We compared changes in respiratory
function and extent of airway inﬂammation between two step-
down approaches, halving the dose of SFC to 100 mg/day or
switching to monotherapy with FP 200 mg/day.Methods
Subjects
This study was conducted at 14 hospitals/clinics in Japan, be-
tween October 2010 and March 2013. Subjects were patients who
met all of the following inclusion criteria: pediatric asthma patients
aged 5e15 years at the start of the study and who had been seen
regularly for at least 6 months prior to entering the study; had
symptoms stabilized with SFC 200 mg/day for at least 12 weeks
prior to the start of the study, had a level of asthma control of 25
points on the Childhood Asthma Control Test (C-ACT) at the end of
the run-in period, had peak expiratory ﬂow (PEF) 80% of the
predicted value at the end of the run-in period, or were able to
undergo spirometry and measurement of exhaled nitric oxide. All
subjects were required to stop taking leukotriene receptor antag-
onists and other controllers before enrollment and allowed usingshort-acting b2-agonists (SABA) and systemic corticosteroid as re-
liever medication throughout this study.
Study design
This study was a randomized, multicenter, open-label, parallel-
group study. A summary of the study design and the CONSORT ﬂow
diagram are shown in Fig.1 and 2, respectively. After enrollment, all
subjects were administered SFC in two puffs (25/50 mg/puff) b.i.d.
via a pressurized metered dose inhaler and with a spacer device
during a run-in period of 4e6 weeks. After the run-in period,
subjects were randomly assigned to an SFC group (25/50 mg b.i.d.)
or an FP group (100 mg b.i.d.). Randomization was performed at the
central data center by using a block randomizationwith a block size
of four. After random allocation, subjects were treated continuously
for 12 weeks. Subjects were seen every 4 weeks, their asthma diary
was checked, and an examination was performed. The subject's C-
ACT score was recorded by caregivers and respiratory function was
measured using an Autospiro spirometer (Minato Medical, Osaka,
Japan). Exhaled nitric oxide (FeNO) was measured with a NIOX
MINO device (Aerocrine; Solna, Sweden) every 4 weeks. We didn't
require the subjects to stop medicines before the lung function test
and the FeNO measuring.
Endpoints
The primary endpoint for this study was the extent of changes in
the%predictedPEFrate (%PEFR). Secondaryendpointswere theextent
of changes in respiratory function, FeNO levels, and the C-ACT score.
Statistical analysis
The rationale for the sample size was a difference in PEF of 7.6 L/
min for two groups in a previous study.4 The standard deviation
was set at 26.0 L/min. Patient allocationwas 1:1, and the a error was
0.05. Statistically calculating the required sample size with a power
of 0.8 resulted in a sample size of 65 patients in each group. A one-
sample t-test was used to compare changes from previous values at
individual measurement points for each group. A two-sample t-test
was used to compare the two groups in terms of measurements and
the extent of changes. All statistical analysis was performed using
SAS version 9.2 software (SAS Institute Inc., Cary, NC, USA).
Ethics
The study protocol was approved by Institutional Review Boards
of Jikei University School of Medicine (21-189 [6067]). During
enrollment, all patients provided informed consent, and written
informed consent was obtained from parents of guardians. The
study was conducted in accordance with the principles embodied
in the Declaration of Helsinki of 1965. This studywas registered as a
clinical trial on November 2, 2010 (UMIN000004498).
Results
Of the 131 study subjects, three had not been using SFC regularly
prior to enrollment. These three patients were excluded from sta-
tistical analysis, resulting in 128 subjects comprising the full
Fig. 1. Study design.
Fig. 2. CONSORT ﬂow diagram. Consort ﬂow diagram for the Optimal step-down approach for pediatric asthma controlled by salmeterol/ﬂuticasone (OSCAR study). A hundred
thirty-one patients provided informed consent, of whom 3 patients didn't receive SFC in run-in period. 10 patients dropped out of this study because asthma exacerbation (3 of FP
group), other controller use (2 of SFC group), lost to follow-up (1 of FP group) and decision by physician (unknown reason) (3 of SFC group and 1 of FP group). The modiﬁed
intention-to-treat analysis was performed in 128 of the 131 subjects who received SFC in run-in period.
Table 1
Baseline characteristics.
SFC (n ¼ 65) FP (n ¼ 63)
Age (year) 9.6 ± 2.0 10.0 ± 2.2
Gender (M/F) 46/19 41/22
Height (cm) 134.1 ± 11.9 137.1 ± 13.7
Weight (kg) 32.2 ± 9.6 34.3 ± 10.7
Sensitization for HDMy (%) 83.1% 82.5%
Comorbidity (ARz) (%) 70.8% 79.4%
PEFR (L/s) 3.9 ± 0.99 4.2 ± 1.2
C-ACTx 26.1 ± 1.3 26.2 ± 0.8
FeNO (ppb) 23.3 ± 22.8 18.0 ± 13.3
Results presented in mean ± s.d. or percentage unless stated otherwise.
y House Dust Mite: Der f1/f2 or Der p1/p2 antigen-speciﬁc IgE concentrations of
more than 0.69 UA/mL were deﬁned as ‘sensitization’.
z Allergic Rhinitis: diagnosed by physician.
x Childhood Asthma Control Test.
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were no signiﬁcant differences between the two groups for age, sex,
asthma severity, respiratory function, or FeNO levels.Lung function
Changes in respiratory function over the study period and re-
sults of inter-group comparisons are shown in Figure 3. The FP
group had a higher mean value for every parameter prior to the
step-down, although the differences between the two groups were
not signiﬁcant at visit 2 (baseline). In the FP group there were
signiﬁcant decreases in the %PEFR and the % predicted forced
expiratory ﬂow at 50% of vital capacity (%V50) from previous
values at each time point. There was a signiﬁcant difference be-
tween the two groups for the extent of the change in %V50 from
its previous value at each time point.
Fig. 3. Changes in respiratory function. A signiﬁcant decrease in the %PEFR (a) and the %V50 (d) from their previous values was shown at each time point in the FP group. Signiﬁcant
differences between the groups were recognized in terms of the extent of the change in %V50 (d) from its previous value at each time point. *p < 0.05, compared to baseline (visit 2,
week 0), paired t-test. **p < 0.01, compared to baseline (visit 2, week 0), paired t-test. yp < 0.05, SFC vs FP, t-test. zp < 0.01, SFC vs FP, t-test.
Fig. 4. Changes in FeNO. Signiﬁcant changes in FeNO levels were not recognized for
both 2 groups. Levels ranged from 15 to 20 ppb.
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As shown in Figure 4, there were no signiﬁcant changes in FeNO
levels (range 15e20 ppb) in either group during the study and no
signiﬁcant difference between the two groups.
C-ACT score
As shown in Figure 5, there were no signiﬁcant changes in the C-
ACT score (~26) in either group during the study and no signiﬁcant
difference between the two groups.
Adverse events
Two patients in the FP group suffered acute bronchitis during
the study period. There were no serious events requiring
hospitalization.
Discussion
The current study examined optimal approaches to stepping
down treatment in asthmatic children whose symptoms had been
stabilized by SFC 200 mg/day. Changes in respiratory function and
the extent of airway inﬂammation were compared between two
groups managed with different step-down approaches, halving the
Fig. 5. Changes in C-ACT. Signiﬁcant changes in the C-ACT score were not recognized
for bothgroup. The score remained around 26 points.
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(100 mg b.i.d.). The current results revealed signiﬁcant decreases in
the %PEFR, an indicator of large airway function, and the %V50, an
indicator of small airway function, from previous values at each
time point in the FP group. In contrast, there were no changes in
those indicators in the SFC group with signiﬁcant differences be-
tween the two groups in terms of the extent of the change in %V50
from its previous value at each time point. There are three possible
mechanisms to explain this ﬁnding. The ﬁrst is the stimulation of b2
receptors by SFC because the salmeterol component of SFC
continued to cause bronchodilation.7,8 The second mechanism may
be relapsing airway inﬂammation after step-down in the FP group.
However, because FeNO levels did not increase and C-ACT scores
did not decrease, this possibility can be ruled out. The third
mechanism relates to the ﬁnding that the FP group had a higher
mean value than the SFC group for every parameter prior to the
step-down, although the differences between the two groups were
not signiﬁcant. The possibility that higher values gave way to
normal levels cannot be ruled out. However, values for the FP group
were the same at visit 1 and visit 2. Switching from SFC to FP is
likely to cause some change in stable respiratory function.
There were no signiﬁcant changes in FeNO levels within or be-
tween the SFC and FP groups. Sorkness et al.6 compared the long-
term (48 weeks) control of mild to moderate persistent asthma in
children aged 6e14 years treated with one of three regimens:
montelukast (5 mg/day); FP (200 mg/day); or SFC (100/100 mg/day).
The authors reported a signiﬁcant increase in forced expiratory
volume in 1 s (FEV1)/forced vital capacity (FVC) and a signiﬁcant
decrease in FeNO levels in patients given FP. FEV1/FVC also
increased in patients given SFC; however, the extent of that in-
crease was signiﬁcantly lesser than that in patients given FP. The
authors also noted a signiﬁcant decrease in FeNO levels; however,
the patients given SFC had a signiﬁcantly smaller percent change
compared with patients given FP.6 Based on these ﬁndings, the
authors concluded that FP 200 mg/day was superior to SFC 100 mg/
day for the long-term control of mild to moderate persistent
asthma in children. There are several reasons to explain why those
results appear to conﬂict with the current ﬁndings. The ﬁrst relates
to differences in the study subjects. Sorkness et al.6 studied children
with unstable asthma symptoms, whereas the children enrolled in
the current study had been stabilized by SFC. In other words, the
current study examined children with sufﬁciently reduced airway
inﬂammation. This could mean that a relapse in airwayinﬂammation that was already well controlled was not noted even
when the SFC dose was halved or the patient was switched to an
equivalent dose of FP. The second reason relates to the method of
administration of SFC. In the current study, SFC 50/25 mg was
administered twice daily whereas Sorkness et al.6 administered SFC
in a double dummy fashion (SFC 100/50 mg in the morning and
salmeterol 50 mg in the evening). Therefore, in the previous study,
SFC in the morning treated inﬂammation while therapy in the
evening was an LABA (bronchodilator) alone. Long-term use of an
LABA alone is reported to exacerbate airway inﬂammation.9,10
Therefore, SFC in the study by Sorkness et al.6 may have had
weaker anti-inﬂammatory action than FP.
There were no signiﬁcant differences in the C-ACT score within
or between the two groups. A high level of control was maintained
over 12 weeks in both the SFC group and the FP group. As
mentioned earlier, slight differences between the two groups were
recognized in terms of changes in respiratory function; however,
therewere no differences in asthmatic symptoms as indicated by C-
ACT scores. Moreover, the C-ACT score remained high throughout
the 12 weeks of step-down. These ﬁndings indicate that halving the
dose of SFC and switching to FP may both be optimal step-down
approaches to asthma therapy in practice.
There are three limitations to the current study that warrant
mention. First, the study was an open trial. The intervention and
assessment were not blinded, so bias may have affected the
assessment. Respiratory function and FeNO levels were the primary
endpoints of the study; however, there are limits to the extent by
which these parameters can be affected. The effects of bias on FeNO
levels can probably be ignored because the subjects were allocated
randomly. In addition, both groups had consistently high C-ACT
scores; hence, there is no need to overestimate the effects of bias.
The second limitation is that medication was not stopped before
the respiratory function tests. Nevertheless, the guidelines on the
Standardization of Spirometry from the American Thoracic Society
makes no speciﬁc mention of stopping medication prior to
testing.11 When the current study was devised, the decision was
made to not stop medication in light of the feasibility of study. As a
result, the data on respiratory function from the current study may
reﬂect residual effects of salmeterol, particularly in the SFC group.
However, the effect on FeNO or C-ACT can be ignored. The third
limitation concerns the C-ACT. The C-ACT with a maximum score of
27 points, is intended for children aged 4e11 years.12 The adult
version of the test, the Asthma Control Test (ACT), with a maximum
score of 25 points, should be used for children aged 12 years and
older.13 However, in the current study, the C-ACT was used for
children aged 12e15 years because differing scores would
complicate the analysis, particularly of children who turned 12
during the study.
In summary, we compared two step-down approaches in asth-
matic childrenwhose symptoms had been stabilized by SFC 200 mg/
day, halving the dose of SFC and switching to FPmonotherapy. Both
approaches resulted in excellent control of asthmatic symptoms (as
indicated by the C-ACT score) for 12 weeks. When the approaches
were assessed based on changes in respiratory function, halving the
dose of SFC proved slightly better. Furthermore, there was no
worsening of airway inﬂammation following step down to half the
dose of SFC. Our ﬁndings suggest that halving the dose of SFC and
switching to FP alone are both optimal step-down approaches.Acknowledgments
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